Limits...
Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction.

Benitez Del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H - Clin Ophthalmol (2014)

Bottom Line: Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life.Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session.No safety or tolerability issues were identified.

View Article: PubMed Central - PubMed

Affiliation: Universidad Complutense, Madrid, Spain.

ABSTRACT
Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life. Eyelid hygiene is the mainstay of treatment but is unstandardized and requires commitment from the patient and encouragement from the ophthalmologist. Blephasteam(®) is an eyelid warming device designed to be an easy-to-use and standardized treatment for MGD. In the present study, 73 patients were treated for 21 days with twice daily Blephasteam(®) sessions. The primary efficacy variable, a symptomatology visual analog scale score, declined from 63.07±21.23 (mean ± standard deviation) on day 0 to 41.90±25.49 on day 21. There were also improvements in a number of secondary efficacy variables including subjective ocular symptoms and clinical signs and symptoms of MGD and dry eye, though tear film breakup time and tear osmolarity were not improved. Global efficacy was assessed as satisfactory or very satisfactory in 83.8% of cases. Patient-reported subjective ocular symptoms declined during the study, and a majority of patients rated the efficacy of Blephasteam(®) as satisfactory or very satisfactory. Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session. No safety or tolerability issues were identified.

No MeSH data available.


Related in: MedlinePlus

The Blephasteam® eyelid-warming device.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4199825&req=5

f1-opth-8-2019: The Blephasteam® eyelid-warming device.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.

Mentions: Blephasteam® is a medical device consisting of a pair of goggles designed to relieve the symptoms of MGD (Figure 1). The eyepieces of the goggles create a warm moist chamber that promotes fluidization of the secretions in the glands, facilitating removal through massage and the application of pressure on the lower eyelids. The alternate current-supplied device was plugged in for 15 minutes, and lights indicated when it was ready for use. Two disposable rings moistened with drinking water were inserted into each eyepiece, and the goggles were worn for 10 minutes, which was timed by the device. Patients were treated with Blephasteam® twice daily for 21 days, allowing at least 4 hours between each session.


Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction.

Benitez Del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H - Clin Ophthalmol (2014)

The Blephasteam® eyelid-warming device.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4199825&req=5

f1-opth-8-2019: The Blephasteam® eyelid-warming device.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
Mentions: Blephasteam® is a medical device consisting of a pair of goggles designed to relieve the symptoms of MGD (Figure 1). The eyepieces of the goggles create a warm moist chamber that promotes fluidization of the secretions in the glands, facilitating removal through massage and the application of pressure on the lower eyelids. The alternate current-supplied device was plugged in for 15 minutes, and lights indicated when it was ready for use. Two disposable rings moistened with drinking water were inserted into each eyepiece, and the goggles were worn for 10 minutes, which was timed by the device. Patients were treated with Blephasteam® twice daily for 21 days, allowing at least 4 hours between each session.

Bottom Line: Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life.Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session.No safety or tolerability issues were identified.

View Article: PubMed Central - PubMed

Affiliation: Universidad Complutense, Madrid, Spain.

ABSTRACT
Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life. Eyelid hygiene is the mainstay of treatment but is unstandardized and requires commitment from the patient and encouragement from the ophthalmologist. Blephasteam(®) is an eyelid warming device designed to be an easy-to-use and standardized treatment for MGD. In the present study, 73 patients were treated for 21 days with twice daily Blephasteam(®) sessions. The primary efficacy variable, a symptomatology visual analog scale score, declined from 63.07±21.23 (mean ± standard deviation) on day 0 to 41.90±25.49 on day 21. There were also improvements in a number of secondary efficacy variables including subjective ocular symptoms and clinical signs and symptoms of MGD and dry eye, though tear film breakup time and tear osmolarity were not improved. Global efficacy was assessed as satisfactory or very satisfactory in 83.8% of cases. Patient-reported subjective ocular symptoms declined during the study, and a majority of patients rated the efficacy of Blephasteam(®) as satisfactory or very satisfactory. Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session. No safety or tolerability issues were identified.

No MeSH data available.


Related in: MedlinePlus